

MUTARS® TUMOR SYSTEM  
 meet you at  
 EMSOS 2009



implantcast GmbH  
 Lüneburger Schanze 26  
 D-21614 Buxtehude  
 phone: +49 4161 744-0  
 fax: +49 4161 744-200  
 e-mail: info@implantcast.de  
[www.implantcast.de](http://www.implantcast.de)

PROVEN MODULARITY

EMSOS 2009 STUTTGART, GERMANY

EMSOS 2009  
 13 – 16 MAY 2009  
 STUTTGART, GERMANY



MAIN PROGRAM AND BOOK OF ABSTRACTS

CONFERENCE

22<sup>ND</sup> ANNUAL MEETING OF THE  
 EUROPEAN MUSCULO-SKELETAL  
 ONCOLOGY SOCIETY (EMSOS)

TRAINING DAY

1<sup>ST</sup> STUTTGART TRAINING DAY ON  
 BONE TUMORS IN CHILDREN AND  
 ADOLESCENTS

SYMPOSIUM

10<sup>TH</sup> SYMPOSIUM OF THE EMSOS  
 NURSES AND ALLIED HEALTH PRO-  
 FESSIONALS GROUP

INDEX:

- 03 WELCOME
- 07 PROGRAM OVERVIEW
- 11 PROGRAM: TRAINING DAY ON BONE  
TUMORS IN CHILDREN AND  
ADOLESCENTS
- 15 PROGRAM: EMSOS NURSES &  
ALLIED PROFESSIONALS GROUP
- 19 EMSOS PROGRAM IN DETAIL
- 38 PROGRAM GPOH RESEARCH FORUM
- 43 ABSTRACTS
- 299 INDEX OF AUTHORS

NAME:

.....



**Innovativ & kompetent –  
Ihr Partner in der Hämatologie**

**Now Enrolling Patients  
With Metastatic Sarcomas**



**Sarcoma Multi-Center Clinical Evaluation  
of the Efficacy of Ridaforolimus**

ARIAD Pharmaceuticals, Inc. and MSD are pleased to announce SUCCEED – a multinational, randomized, Phase 3, double-blind, placebo-controlled trial to determine the efficacy and safety of oral ridaforolimus (formerly deforolimus) when administered as maintenance therapy to patients with metastatic soft-tissue or bone sarcomas who have had a favorable outcome to chemotherapy.

To learn more about the SUCCEED trial, or to find a trial site nearby, please call the international number **1-617-621-2302** or visit **www.ClinicalTrials.gov** (NCT00538239).

ARIAD Pharmaceuticals, Inc. and MSD have a global collaboration to jointly investigate ridaforolimus for the treatment of cancer.

